Five Prime Therapeutics (NASDAQ:FPRX)

CAPS Rating: 5 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar pchop12316 (72.29) Submitted: 12/19/2014 2:50:37 PM : Outperform Start Price: $24.98 FPRX Score: +3.93

looks more like a big winner every day

Recs

0
Member Avatar sullyz0r (73.79) Submitted: 11/26/2014 10:42:42 AM : Outperform Start Price: $20.78 FPRX Score: +24.99

I've liked FPRX for a while. Entering this as my "rich get richer" pick, along with $AGIO

Recs

0
Member Avatar pchop123 (80.37) Submitted: 8/7/2014 11:29:31 AM : Outperform Start Price: $12.14 FPRX Score: +105.72

time for a substantial rebound

Recs

0
Member Avatar simplemts (< 20) Submitted: 4/12/2014 8:21:13 PM : Outperform Start Price: $14.65 FPRX Score: +63.83

i like it

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 4/8/2014 12:24:43 AM : Outperform Start Price: $16.18 FPRX Score: +48.13

Given the market cap inflation that has accompanied oncology IPO's since mid 2013, it's a little incongruous to see an outfit like Five Prime with a market cap under 350M. A quick overview doesn't indicate any obvious reason for the weak valuation. The company has a partnership with GSK for FP-1039 extracellular ligand trap which is already in clinical development, along with a recently announced partnership with Bristol Myers on preclinical immuno-oncology candidates. The latter collaboration was accompanied by a 20M upfront payment, a fairly respectable sum just for use of Five Prime's drug discovery platform. The 62M IPO last September was also solid, if not a blockbuster.

Despite their apparent undervaluation when compared to the rest of the oncology IPO class of 2013, Five Prime doesn't have any late stage pipeline candidates and therefore has a great deal to prove. However, zzporte has decided to follow up recent successful ventures with Stemline and Agios with a starter 200 share position in Five Prime at 16.64.

Results 1 - 5 of 5

Featured Broker Partners


Advertisement